Roche’s Kadcyla Fails To Better Herceptin In First-Line Breast Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Sales estimates for Roche’s Kadcyla will be cut sharply after news the MARIANNE study didn’t show the antibody-drug conjugate performing better than Herceptin in treating first-line breast cancer. Firm’s early Alzheimer’s therapy gantenerumab also fails in Phase III.
You may also be interested in...
After almost two decades at Millennium/Takeda, Anna Protopapas moves to tiny Mersana Therapeutics, which aims to power up oncology with its Fleximer drug conjugate platform.
MARIANNE frontline breast cancer trial failure was a blow, but HER2 franchise remains strong overall, particularly with the survival results from the CLEOPATRA study and other key studies due to report, company argues.
Roche’s key HER2 breast cancer franchise boasted a stellar sales performance in the first-quarter – rising 27% in the U.S. alone – and the rest of the cancer business followed suit. But, the loss of schizophrenia candidate bitopertin casts a shadow on the firm’s plans for neuroscience.